Navalign LLC Invests $201,000 in AstraZeneca PLC $AZN

Navalign LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 2,625 shares of the company’s stock, valued at approximately $201,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of AstraZeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of AstraZeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after buying an additional 11,690 shares during the period. Golden State Wealth Management LLC raised its holdings in AstraZeneca by 20.1% in the 2nd quarter. Golden State Wealth Management LLC now owns 987 shares of the company’s stock valued at $69,000 after buying an additional 165 shares during the last quarter. Modera Wealth Management LLC acquired a new stake in AstraZeneca during the 2nd quarter worth approximately $204,000. Finally, Savant Capital LLC boosted its position in AstraZeneca by 15.2% during the 2nd quarter. Savant Capital LLC now owns 53,489 shares of the company’s stock worth $3,738,000 after buying an additional 7,050 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.6%

Shares of NASDAQ AZN opened at $194.44 on Monday. The company has a market capitalization of $301.56 billion, a P/E ratio of 64.60, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32. AstraZeneca PLC has a 52-week low of $122.48 and a 52-week high of $212.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The company’s 50 day moving average price is $146.71 and its 200-day moving average price is $106.62.

AstraZeneca Announces Dividend

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s payout ratio is presently 66.26%.

Analysts Set New Price Targets

Several brokerages have issued reports on AZN. HSBC restated a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.